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Inhibition of histone deacetylases (HDACs) is a promising approach for the treatment of 
mood disorders. However, the effects of HDAC inhibition on the serotonin (5-HT) 
system, a common target for psychiatric disorders, are poorly understood. Here, we 
show that a broad-spectrum HDAC inhibitor, trichostatin A (TSA), enhances the 
function of 5-HT neurons in organotypic raphe slice cultures. Sustained treatment with 
TSA (1 μM) for 2 or 4 days significantly increased the 5-HT tissue content and 
tryptophan hydroxylase 2 (TPH2) expression, which were accompanied by 
hyper-acetylation of histone H3 in the promoter region of the TPH2 gene. TSA 
treatment for 4 days increased the extracellular 5-HT level, which was significantly 
suppressed in the presence of the selective AMPA receptor (AMPAR) antagonist NBQX. 
Moreover, the expression of both the AMPAR subunit GluA2 and 
Ca2+/calmodulin-dependent kinase II α (CaMKIIα) mRNAs were significantly increased 
by TSA treatment. Co-treatment with the CaMKII inhibitors KN-62 and KN-93 
prevented the TSA-induced increase in 5-HT release, but had no effect on the increases 
in 5-HT tissue content. These results suggest that inhibition of HDACs increases 5-HT 
synthesis and release by epigenetic mechanisms, and that 5-HT release is mediated by 
the enhancement of AMPAR-mediated excitatory inputs and CaMKII signaling. 
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Chromatin modification is one mechanism of epigenetic gene regulation that changes 
gene expression and cellular function without changing the DNA sequence [1]. Histone 
acetylation enhances mRNA transcription, and is regulated by the balance between 
histone acetyltransferase and histone deacetylase (HDAC). HDAC inhibitors increase 
the acetylation of histones at lysine residues and enhance gene expression [2]. Growing 
evidence suggests that epigenetic mechanisms affect an individual’s vulnerability to 
psychiatric disorders [3]. Environmental factors, such as early-life stress and chronic 
stress, can change epigenetic modifications to alter the response to further stress [4]. 
While HDAC inhibitors are clinically used as anticancer agents, recent evidence 
suggests a therapeutic potential for HDAC inhibitors in the treatment of psychiatric 
disorders such as depression [5-7]. However, the mechanisms by which HDAC 
inhibitors exhibit an antidepressant effect are not fully understood. 
The serotonin (5-HT) system plays a key role in pathogenic mechanisms and 
treatment of mood disorders. In animal models of chronic stress, the activity of 5-HT 
neurons in the dorsal raphe nuclei (DRN) is decreased [8]. On the other hand, 
conventional antidepressants such as selective serotonin reuptake inhibitors (SSRIs) 
potentiate 5-HT signaling by increasing extracellular 5-HT levels, while it takes several 
weeks to show therapeutic effects [9]. Several studies suggest that not only acute effects, 
i.e., serotonin transporter inhibition, but also chronic changes, including epigenetic 
modification, play important roles in the therapeutic effects induced by SSRIs [10, 11]. 
However, whether epigenetic modification of the 5-HT system is involved in the 
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antidepressant effect of HDAC inhibitors is currently unclear. 
We previously reported that organotypic raphe slice cultures that possess functional 
5-HT neurons and local neuronal circuits provide a useful tool for investigation of the 
effects of antidepressants on the 5-HT system [12, 13]. In this study, we examined 
whether a pan-HDAC inhibitor, trichostatin A (TSA), affects 5-HT neuronal function 
using organotypic raphe slice cultures.  
 
2. Materials and Methods 
Details are presented in the Supplementary Materials and Methods. 
 
2.1. Preparation of rat organotypic raphe slice cultures 
All animal care and experimental procedures were conducted in accordance with the 
ethical guidelines of the Kyoto University Animal Research Committee. Rat raphe slice 
cultures were prepared as previously described [12, 13]. Briefly, coronal sections (350 
μm thick) containing the dorsal and median raphe nuclei were prepared from Wistar/ST 
rat pups, and maintained in culture for 14–16 days. 
 
2.2. Measurement of tissue contents and extracellular levels of 5-HT 
Tissue contents and extracellular levels of 5-HT were measured as previously 
described [13]. Briefly, for measurement of tissue contents of 5-HT, the brain slices 
were homogenized and centrifuged, and the supernatants were analyzed by high 
performance liquid chromatography with an electrochemical detector (HPLC-ECD) 
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(Eicom, Kyoto, Japan). For measurement of extracellular 5-HT levels, slices were 
incubated in 0.7 mL Krebs-Ringer-Henseleit (KRH) buffer in the presence of citalopram 
(1 μM) for 30 min. The 5-HT concentration in the conditioned KRH buffer was 
measured by HPLC-ECD. 
 
2.3. Real-time RT-PCR 
Raphe slice cultures were cut and 1/3 of both lateral sides and 1/4 of the dorsal side 
was removed to isolate the raphe. Total mRNA was isolated from the slices, and reverse 
transcribed. Real-time quantitative PCR for glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), tryptophan hydroxylase 2 (TPH2), GluA1, GluA2 and 
Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα) were performed. 
 
2.4. Western blot 
Western blot analysis for TPH was performed as previously described [12, 13]. 
Briefly, proteins extracted from slices were subjected to SDS-PAGE. Resolved proteins 




Immunohistochemistry for TPH was performed as previously described [12]. Fixed, 
permeabilized and blocked slices were incubated with an anti-TPH antibody, followed 




2.6. Quantitative chromatin immunoprecipitation (ChIP) assay 
Chromatin samples prepared from slices were incubated with an anti-acetyl-histone 
H3 antibody. Antibody conjugated chromatin was precipitated using Protein G-coupled 
Dynabeads. Acetylated histone H3 levels in the upstream regions of the TPH2, GluA2 
or CaMKIIα genes were analyzed by quantitative PCR (qPCR). 
 
2.7. Statistical analysis 
All data are presented as the mean ± S.E.M. Differences between two groups were 
compared by Student’s t-test. Data with more than two groups were compared using a 
one-way or two-way analysis of variance (ANOVA) followed by the Bonferroni post 




3.1. TSA treatment increased 5-HT synthesis by increasing TPH2 gene transcription 
To examine whether TSA increases 5-HT synthesis, slices were treated with vehicle 
or TSA (1 μM) for 1, 2 or 4 days. Sustained treatment with vehicle had no effect on the 
tissue content of 5-HT, or of 5-hydroxyindolacetic acid (control: 0.74 ± 0.07 nmol/mg 
protein; 2 days: 0.59 ± 0.02 nmol/mg protein; 4 days: 0.67 ± 0.13 nmol/mg protein; n = 
3), while the TSA treatment significantly increased the tissue content of 5-HT, 
compared with vehicle-treated slices (TSA effect: F1,24 = 21.91, P < 0.001; time effect: 
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F2,24 = 7.73, P < 0.01; TSA × time interaction: F2,24 = 1.65, P = 0.2137) (Fig. 1A). The 
level of TPH2 mRNA was significantly increased by 2 or 4 days of treatment (F3,14 = 
10.58, P < 0.01) (Fig. 1B). TSA treatment for 4 days significantly increased TPH 
protein levels (Fig. 1C). Immunostaining for TPH showed that TSA treatment increased 
the fluorescence intensity of the TPH-positive cells in the raphe slices, while it had no 
effect on the morphology (Fig. 1D). Furthermore, pan-acetylation levels of histone H3 
in the upstream region of the TPH2 gene were significantly increased (F3,14 = 3.792, P < 
0.05) after 2 days of TSA treatment, but not after 1 or 4 days (Fig. 1E). 
 
3.2. TSA treatment increased 5-HT release from organotypic raphe slice cultures 
We examined whether TSA treatment affected the 5-HT release from raphe 5-HT 
neurons. Acute treatment with TSA (0.1–10 μM) for 30 min in KRH buffer did not 
change the extracellular 5-HT level (Fig. 2A), whereas sustained treatment for 4 days 
significantly increased the extracellular 5-HT levels in a concentration-dependent 
manner (F3,10 = 15.06, P < 0.001) (Fig. 2B). Sustained treatment with TSA (1 μM) for 
1–4 days significantly increased the extracellular 5-HT levels (TSA effect: F1,12 = 24.17, 
P < 0.001; time effect: F2,12 = 5.96, P < 0.05; TSA × time interaction: F2,12 = 4.81, P < 
0.05). A significant increase was observed after 4 days of treatment (Fig. 2C), which 
was delayed compared to the increase in 5-HT tissue content. Similarly, sustained 
treatment with another HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA; 1 and 
10 μM), for 4 days significantly increased the extracellular 5-HT levels (F2,10 = 21.79, P 
< 0.001) (Fig. 2D). We previously reported that sustained treatment with SSRIs 
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dramatically enhanced exocytotic 5-HT release in the raphe slice cultures [13]. Here, we 
examined whether TSA treatment further augments the enhanced 5-HT release in 
response to sustained treatment with an SSRI, citalopram. Consistent with our previous 
report [13], sustained treatment with citalopram (1 μM) for 4 days increased the 
extracellular 5-HT level (F1,23 = 13.72, P < 0.01). Sustained co-treatment with TSA (1 
μM) significantly augmented the elevated 5-HT level by sustained citalopram treatment 
(F1,23 = 77.25, P < 0.001), although a two-way ANOVA revealed no interaction between 
citalopram and TSA (F1,23 = 2.56, P = 0.123) (Fig. 2E). 
 
3.3. TSA treatment increased the expression levels of the 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) and CaMKII 
Since HDAC inhibitors potentiate excitatory synaptic function by increasing gene 
transcription [14, 15], we examined whether AMPAR-mediated excitatory inputs were 
involved in the TSA-induced increase in 5-HT release. The increase in 5-HT release in 
response to 4 days of TSA treatment (1 μM) was significantly suppressed in the 
presence of the selective AMPAR antagonist NBQX (30 μM) (Fig. 3A). We next 
examined the gene expression of AMPAR subunits and CaMKIIα, which plays an 
important role in AMPAR trafficking [16] (Fig. 3B-D). TSA treatment (1 μM) for 1–4 
days significantly increased the mRNA levels of GluA2 (F3,11 = 10.98, P < 0.01) and 
CaMKIIα (F3,11 = 8.707, P < 0.01). The level of GluA1 mRNA also tended to be 
increased by TSA treatment, but the effect was not significant (F3,11 = 2.006, P = 
0.1715). Furthermore, TSA treatment significantly increased pan-acetylation levels of 
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histone H3 in the upstream regions of the GluA2 and CaMKIIα genes (F3,14 = 12.59, P 
< 0.001, and F3,12 = 3.017, P < 0.05, respectively). The increases peaked after 2 days of 
treatment, and tended to return to basal levels by 4 days of treatment (Fig. 3E, F).  
 
3.4. CaMKII signaling is required for the TSA-induced increase in 5-HT release, but not 
5-HT synthesis 
We examined whether CaMKII-mediated signaling is involved in the effects of TSA. 
Co-treatment with the CaMKII inhibitors, KN-62 (10 μM) or KN-93 (10 μM), and TSA 
(1 μM) for 4 days significantly blocked the TSA-induced increase in 5-HT release 
(KN-62 × TSA interaction: F1,12 = 6.22, P < 0.05 and KN-93 × TSA interaction: F1,8 = 
6.61, P < 0.05, respectively), while they failed to affect the TSA-induced increase in 
5-HT tissue content (KN-62 × TSA interaction: F1,12 = 0.07, P = 0.79 and KN-93 × TSA 
interaction: F1,8 = 0.77, P = 0.4057, respectively) (Fig. 4). 
 
4. Discussion 
In this study, we showed that prolonged treatment with the broad-spectrum HDAC 
inhibitor TSA increased 5-HT synthesis and release in organotypic raphe slice cultures. 
This effect was mediated primarily through the enhancement of gene expression related 
to 5-HT synthesis and excitatory inputs. These data suggest that inhibition of HDACs 
potentiates the function of 5-HT neurons by an epigenetic mechanism. 
TPH2 is a rate-limiting enzyme for 5-HT synthesis in the central nervous system [17]. 
While the mechanisms that control TPH2 expression are not fully understood, several 
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reports suggest that the neuron-restrictive silencer factor, which recruits corepressor 
complexes containing HDAC1/2 [18], negatively regulates TPH2 expression [19]. 
Consistent with these reports, the increase in TPH2 expression was accompanied by 
hyper-acetylation of histone H3 at the promoter region of the TPH2 gene in the raphe 
slice cultures. By contrast, HDAC6 that exists mainly in the cytosol indirectly regulates 
TPH2 expression by modulating nuclear transport of glucocorticoid receptors [20]. 
Since TSA also inhibits HDAC6, inhibition of HDAC6 may also be involved in 
TSA-induced increases in 5-HT synthesis in the raphe slice cultures, although possible 
involvement of other off-target effects of TSA and SAHA cannot be excluded. 
AMPAR-mediated excitatory inputs regulate the DRN 5-HT neuronal activity and 
5-HT release [13, 21]. Several lines of evidence suggest that HDAC inhibitors enhance 
excitatory synaptic function and plasticity in a transcription-dependent manner [14, 15]. 
Consistent with the present results, class I HDACs that are specifically localized in the 
nucleus control the expression of the AMPAR subunit GluA2 [22] and of CaMKIIα [23]. 
CaMKII promotes AMPAR trafficking [24] and gating [25]. Taken together, the results 
of this study suggest that inhibition of HDACs enhances CaMKII signaling, and 
consequently, contributes to the increase in 5-HT release through the enhancement of 
AMPAR-mediated excitatory inputs, although the enhanced CaMKII signaling is not 
involved in increased 5-HT synthesis. However, considering the concentration we used 
in this study, we cannot rule out the possible involvement of other kinases which KN-62 
and KN-92 may weakly inhibit. Furthermore, additional research will be needed to 
clarify the contribution of non-5-HT neurons and glial cells in the raphe slice cultures to 
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the effects of the HDAC inhibitors. 
Recent evidence suggests that chronic stress exposure decreases TPH2 expression in 
the DRN [26]. By contrast, chronic treatment with the SSRI fluoxetine increases TPH2 
expression in the midbrain, which is correlated with the antidepressant-like effect in the 
forced swim test [27]. In this context, our present results suggest that the increased 
TPH2 expression in response to the HDAC inhibitor may indicate that such inhibitors 
can be used in the treatment of psychiatric disorders. We previously demonstrated that 
the sustained SSRI-induced elevation of extracellular 5-HT levels is caused by the 
facilitation of AMPAR-mediated exocytotic 5-HT release, but not by increases in 5-HT 
synthesis [13]. Therefore, it is conceivable that a TSA-induced increase in 5-HT 
synthesis and AMPAR-mediated 5-HT release by epigenetic mechanisms can further 
enhance the effects of SSRIs. 
In the present study, we used broad-spectrum HDAC inhibitors, TSA and SAHA, 
which potently inhibit both class I HDACs and class II HDACs, such as HDAC5 and 
HDAC6 [28]. Class II HDACs exist both in the nucleus and cytosol, and catalyze lysine 
acetylation of various proteins other than histones. In addition to class II HDACs, class 
I HDACs may also be responsible for the antidepressant effect [6, 10, 20]. Although we 
showed that TSA increased gene expression, potentially by histone H3 hyper-acetylation, 
we cannot exclude the possibility that cytoplasmic HDACs are involved as well. 
Furthermore, it is possible that anti-inflammatory effect of HDAC inhibitors on glial 
cells [29] may affect excitatory inputs to 5-HT neurons. 
In conclusion, we have shown that sustained treatment with the HDAC inhibitor TSA 
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increased AMPAR-mediated 5-HT release from the raphe slice cultures, through the 
enhancement of 5-HT synthesis and CaMKII signaling by epigenetic mechanisms. 
Although it has not been determined whether TSA itself exhibits antidepressant effects, 
our results suggest that the inhibition of HDACs potentiates the function of the 5-HT 
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Fig. 1. Sustained treatment with TSA enhanced 5-HT synthesis by increasing TPH2 
expression. Slices were treated with vehicle or TSA (1 μM) for 1, 2 or 4 days. (A) 5-HT 
tissue content. **P < 0.01 vs vehicle. n = 3–8. (B) qPCR for TPH2. n = 3–4. (C) 
Western blot analysis of TPH. n = 3. (D) Representative images of TPH 
immunoreactivity in the slices. Scale bar = 40 μm. (E) ChIP assays were performed 
using an anti-acetyl-histone H3 antibody. qPCR for the upstream region of the TPH2 





Fig. 2. Sustained treatment with TSA or SAHA increased extracellular 5-HT levels in 
the raphe slice cultures. (A-D) Slices were treated with TSA (0.1–10 μM) for 30 min (A; 
n = 3–6) or 4 days (B; n = 3–4), with TSA (1 μM) for 1, 2 or 4 days (C; n = 3), or with 
SAHA (1 or 10 μM) for 4 days (D; n = 3–6), and extracellular 5-HT levels were 
measured. VEH: vehicle. *P < 0.05, **P < 0.01, ***P < 0.001 vs vehicle or control. (E) 
Effect of TSA on the enhanced 5-HT release in response to sustained SSRI treatment. 
Slices were co-treated with TSA (1 μM) and citalopram (1 μM) for 4 days, and the 





Fig. 3. TSA treatment enhanced AMPAR-mediated input by increasing the mRNA 
levels of AMPAR and CaMKIIα. (A) Slices were treated with vehicle or TSA (1 μM) 
for 4 days, and extracellular 5-HT levels were measured in the presence or absence of 
the AMPAR antagonist NBQX (30 μM). VEH: vehicle. n = 3–4. (B-F) Slices were 
treated with TSA (1 μM) for 1, 2 or 4 days, and qPCR for GluA1 (B), GluA2 (C), or 
CaMKIIα (D) was performed. n = 3–4. (E, F) ChIP assays were performed using an 
anti-acetyl-histone H3 antibody. qPCR for the upstream regions of the GluA2 (E) and 






Fig. 4. CaMKII signaling is necessary for TSA-induced increase in 5-HT release, but 
not in 5-HT tissue content. Slices were co-treated with TSA (1 μM) and the CaMKII 
inhibitors KN-62 (10 μM) or KN-93 (10 μM) for 4 days. Extracellular 5-HT level and 
5-HT tissue content were measured. n = 3–4. N.S.: not significant, *P < 0.05, **P < 
0.01. 
